标签归档：抑制

Linderalactone

发表于由

上海金畔生物科技有限公司提供天然产物萜类及其苷类Terpenoids and Glycosides。

Linderalactone  纯度: ≥98.0%

Linderalactone 是从 Radix linderae 中分离出来的一种重要的倍半萜烯内酯。Linderalactone 通过调节凋亡相关蛋白的表达和抑制 JAK/STAT 信号通路来抑制癌细胞生长。Linderalactone 还以 IC50 值为 15 µM 来抑制肺癌 A-549 细胞的增殖。

Linderalactone

Linderalactone Chemical Structure

CAS No. : 728-61-0

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1800 In-stock
5 mg ￥2020 In-stock
10 mg ￥3430 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Linderalactone 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Macrocyclic Compound Library
  • Terpenoids Library
  • Traditional Chinese Medicine Monomer Library
  • Anti-Lung Cancer Compound Library

生物活性

Linderalactone is an important sesquiterpene lactone isolated from Radix linderae. Linderalactone inhibits cancer growth by modulating the expression of apoptosis-related proteins and inhibition of JAK/STAT signalling pathway. Linderalactone also inhibits the proliferation of the lung cancer A-549 cells with an IC50 of 15 µM[1][2].

体外研究
(In Vitro)

Linderalactone (0-100 μM; 24 hours; A549 cells) treatment inhibits the growth of A549 cells concentration-dependently. The IC50 of linderalactone is 15 µM[1].
Linderalactone (7.5-30 μM; A549 cells) treatment induces apoptosis in A549 cells in a dose-dependent manner[1].
Linderalactone (7.5-30 μM; 24 hours; A549 cells) treatment induces G2/M cell cycle arrest of A549 cells dose-dependently[1].
Linderalactone (7.5-30 μM; A549 cells) inhibits the expression of STAT1, JAK1 and JAK2. Linderalactone could also inhibit the phosphorylation of pSTAT1, pSTAT-2, pJAK1 and pJAk2[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: Lung cancer A549 cells
Concentration: 0 μM, 1.6 μM, 3.2 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM
Incubation Time: 24 hours
Result: Inhibited the growth of A549 cells concentration-dependently.

Apoptosis Analysis[1]

Cell Line: Lung cancer A549 cells
Concentration: 7.5 μM, 15 μM, 30 μM
Incubation Time:
Result: Induced apoptosis in A549 cells in a dose-dependent manner.

Cell Cycle Analysis[1]

Cell Line: Lung cancer A549 cells
Concentration: 7.5 μM, 15 μM, 30 μM
Incubation Time: 24 hours
Result: Induced G2/M cell cycle arrest.

Western Blot Analysis[1]

Cell Line: Lung cancer A549 cells
Concentration: 7.5 μM, 15 μM, 30 μM
Incubation Time:
Result: Inhibited the JAK/STAT pathway in A549 cells.

分子量

244.29

Formula

C15H16O3
CAS 号

728-61-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶解性数据
In Vitro: 

DMSO : 33.33 mg/mL (136.44 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.0935 mL 20.4675 mL 40.9350 mL
5 mM 0.8187 mL 4.0935 mL 8.1870 mL
10 mM 0.4093 mL 2.0467 mL 4.0935 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (10.23 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (10.23 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (10.23 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (10.23 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献

  • [1]. Deng Y, et al. Linderalactone inhibits human lung cancer growth by modulating the expression of apoptosis-related proteins, G2/M cell cycle arrest and inhibition of JAK/STAT signalling pathway. J BUON. 2019 Mar-Apr;24(2):566-571.

    [2]. Qinghua Sun, et al. Preparative Isolation and Purification of Linderalactone and Lindenenol from Radix linderae by HSCCC. Journal of Liquid Chromatography & Related Technologies. Aug 2005:113-121.

Wedelolactone(Synonyms: 蟛蜞菊内酯)

发表于由

天然产物 天然产物苯丙素类 Phenylpropanoids

Wedelolactone (Synonyms: 蟛蜞菊内酯) 纯度: 99.70%

Wedelolactone，是一种来自 Ecliptae herba 的天然产物，通过直接抑制 IKK 复合物来抑制 LPS 诱导的 caspase-11 表达。Wedelolactone 通过氧自由基清除机制抑制 5-脂氧合酶 (5-lipoxygenase, 5-Lox) (IC50~2.5 μM) 活性。Wedelolactone 通过下调 PKCε 诱导前列腺癌细胞中 caspase 依赖性细胞凋亡 (apoptosis) 而不抑制 Akt。具有抗癌，抗炎和抗氧化活性。

Wedelolactone(Synonyms: 蟛蜞菊内酯)

Wedelolactone Chemical Structure

CAS No. : 524-12-9

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥553 In-stock
5 mg ￥800 In-stock
10 mg ￥1400 In-stock
20 mg ￥2300 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Wedelolactone 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Ferroptosis Compound Library
  • Medicine Food Homology Compound Library
  • Phenols Library
  • Pyroptosis Compound Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved & Pharmacopeial Drug Library
  • Lipid Metabolism Compound Library
  • Targeted Diversity Library

生物活性

Wedelolactone, a natural product from Ecliptae herba, suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK Complex[1]. Wedelolactone inhibits 5-lipoxygenase (5-Lox) (IC50~2.5 μM) activity by an oxygen radical scavenging mechanism. Wedelolactone induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt[2]. Anti-cancer, anti-inflammatory, and antioxidant activities[3].

IC50 & Target[1][2][3]

Caspase-11

 

5-LOX

2.5 μM (IC50)

Apoptosis

 

分子量

314.25

Formula

C16H10O7
CAS 号

524-12-9
中文名称

蟛蜞菊内酯；蟛蜞内酯；蟛蜞菊内脂
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 125 mg/mL (397.77 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.1822 mL 15.9109 mL 31.8218 mL
5 mM 0.6364 mL 3.1822 mL 6.3644 mL
10 mM 0.3182 mL 1.5911 mL 3.1822 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (6.62 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (6.62 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (6.62 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (6.62 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Kobori M, et al. Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ. 2004 Jan;11(1):123-30.

    [2]. Sarveswaran S, et al. Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. Int J Oncol. 2012 Dec;41(6):2191-9.

    [3]. Liu YQ, et al. Wedelolactone enhances osteoblastogenesis by regulating Wnt/β-catenin signaling pathway but suppresses osteoclastogenesis by NF-κB/c-fos/NFATc1 pathway. Sci Rep. 2016 Aug 25;6:32260.

Cynaropicrin

发表于由

上海金畔生物科技有限公司提供天然产物萜类及其苷类Terpenoids and Glycosides。

Cynaropicrin  纯度: 97.16%

Cynaropicrin 是一种倍半萜内酯，可以抑制肿瘤坏死因子 (TNF-α) 的释放，在鼠和人巨噬细胞的 IC50 值分别为 8.24 和 3.18 μM。 Cynaropicrin 也抑制软骨降解因子 (MMP13) 的增加并抑制 NF-κB 的信号传导。

Cynaropicrin

Cynaropicrin Chemical Structure

CAS No. : 35730-78-0

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥4950 In-stock
5 mg ￥4500 In-stock
10 mg ￥6500 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Cynaropicrin 相关产品

•相关化合物库:

  • Covalent Screening Library Plus
  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Immunology/Inflammation Compound Library
  • Metabolism/Protease Compound Library
  • NF-κB Signaling Compound Library
  • Stem Cell Signaling Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Covalent Screening Library
  • Antioxidants Compound Library
  • Differentiation Inducing Compound Library
  • Oxygen Sensing Compound Library
  • Terpenoids Library
  • Pyroptosis Compound Library
  • Traditional Chinese Medicine Monomer Library
  • Anti-Breast Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Obesity Compound Library
  • Angiogenesis Related Compound Library
  • Transcription Factor Targeted Library
  • Food-Sourced Compound Library
  • Anti-Liver Cancer Compound Library

生物活性

Cynaropicrin is a sesquiterpene lactone which can inhibit tumor necrosis factor (TNF-α) release with IC50s of 8.24 and 3.18 μM for murine and human macrophage cells, respectively. Cynaropicrin also inhibits the increase of cartilage degradation factor (MMP13) and suppresses NF-κB signaling.

IC50 & Target[1][2]

MMP13

 

NF-κB

 

TNF-α

 

体外研究
(In Vitro)

Cynaropicrin strongly inhibits lipopolysaccharide-induced TNF-α release from either murine or human macrophage cells in a dose-dependent manner with the IC50 values of 8.24 and 3.18 μM, respectively. Cynaropicrin shows significant inhibitory effects toward all mitogenic signals with the IC50 values of 1.20 (concanavalin A), 1.02 (phytohemagglutinin) and 0.90 μM (lipopolysaccharide), respectively. Cynaropicrin suppresses CTLL-2 cell proliferation in a dose-dependent manner and the 50% inhibitory concentration (IC50) of Cynaropicrin for CTLL-2 cell growth is 0.91 μM[1]. The increased mRNA expression of MMP13 induced by TNF-α is similarly inhibited in a concentration-dependent manner by Cynaropicrin. The increased mRNA expression of HIF-2α induced by IL-1β in SW1353 is inhibited in a concentration-dependent manner by Cynaropicrin[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

346.37

Formula

C19H22O6
CAS 号

35730-78-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶解性数据
In Vitro: 

DMSO : ≥ 50 mg/mL (144.35 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.8871 mL 14.4354 mL 28.8709 mL
5 mM 0.5774 mL 2.8871 mL 5.7742 mL
10 mM 0.2887 mL 1.4435 mL 2.8871 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.22 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.22 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (7.22 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.22 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献

  • [1]. Cho JY, et al. In vitro anti-inflammatory effects of cynaropicrin, a sesquiterpene lactone, from Saussurea lappa. Eur J Pharmacol. 2000 Jun 23;398(3):399-407.

    [2]. Masutani T, et al. Cynaropicrin is dual regulator for both degradation factors and synthesis factors in the cartilage metabolism. Life Sci. 2016 Aug 1;158:70-7.

    [3]. da Silva CF, et al. Activities of psilostachyin A and cynaropicrin against Trypanosoma cruzi in vitro and in vivo. Antimicrob Agents Chemother. 2013 Nov;57(11):5307-14.
Cell Assay
[1]

Human U937 cells are cultured in RPMI1640 supplemented with 10% fetal bovine serum. To differentiate U937 cells, 2×106 cells/mL are treated with phorbol 12-myristate 13-acetate (PMA) of 20 ng/mL for 24 h. The PMA is removed by washing and adherent cells are then allowed to recuperate for 40 h. The recuperated cells are subsequently incubated with lipopolysaccharide of 1 μg/mL for 6 h with Cynaropicrin and positive control drugs. Supernatants are harvested and assayed by ELISA kit for human TNF-α[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[3]

Male Swiss mice are used in this study. Mice are housed at a maximum of 8 per cage and kept in a conventional room at 20 to 24°C under a 12 h to 12 h light-dark cycle. The animals are provided with sterilized water and chow ad libitum. Infection is performed by i.p. injection of 104 or 5×103 bloodstream trypomastigotes. The animals (18 to 21 g) are divided into the following groups (at least five mice per group): uninfected (noninfected and untreated), untreated (infected with T. cruzi but treated only with vehicle), and treated (infected and treated i.p. with 0.5 to 50 mg/kg/day compound (including Cynaropicrin) or 100 mg/kg/day benznidazole). Mice receive 0.1 mL (i.p.) at 5 and 8 days postinfection (dpi), or at 11, 12, and 13 dpi for the dose of 25 mg/kg, twice a day (b.i.d.)[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Cho JY, et al. In vitro anti-inflammatory effects of cynaropicrin, a sesquiterpene lactone, from Saussurea lappa. Eur J Pharmacol. 2000 Jun 23;398(3):399-407.

    [2]. Masutani T, et al. Cynaropicrin is dual regulator for both degradation factors and synthesis factors in the cartilage metabolism. Life Sci. 2016 Aug 1;158:70-7.

    [3]. da Silva CF, et al. Activities of psilostachyin A and cynaropicrin against Trypanosoma cruzi in vitro and in vivo. Antimicrob Agents Chemother. 2013 Nov;57(11):5307-14.

Hesperidin methylchalcone

发表于由

天然产物 黄酮类 Flavonoids

Hesperidin methylchalcone  纯度: ≥98.0%

Hesperidin methylchalcone (Hesperidin methyl chalcone) 抑制氧化应激，细胞因子产生和 NF-κB 活化。Hesperidin methylchalcone 抑制炎症和疼痛。且具有血管保护活性。

Hesperidin methylchalcone

Hesperidin methylchalcone Chemical Structure

CAS No. : 24292-52-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥550 In-stock
500 mg ￥500 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Hesperidin methylchalcone 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • NF-κB Signaling Compound Library
  • Stem Cell Signaling Compound Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Differentiation Inducing Compound Library
  • Glycoside Compound Library
  • Oxygen Sensing Compound Library
  • Pyroptosis Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Parkinson’s Disease Compound Library
  • Neurodegenerative Disease-related Compound Library
  • Anti-Obesity Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library

生物活性

Hesperidin methylchalcone (Hesperidin methyl chalcone) inhibits oxidative stress, cytokine production and NF-κB activation. Hesperidin methylchalcone inhibits inflammation and pain. Hesperidin methylchalcone exhibits vasoprotective activity[1].

IC50 & Target[1]

NF-κB

 

分子量

624.59

Formula

C29H36O15
CAS 号

24292-52-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (80.05 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.6011 mL 8.0053 mL 16.0105 mL
5 mM 0.3202 mL 1.6011 mL 3.2021 mL
10 mM 0.1601 mL 0.8005 mL 1.6011 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (3.33 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.33 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (3.33 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.33 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献

  • [1]. Pinho-Ribeiro FA, et al. Protective effects of the flavonoid hesperidin methyl chalcone in inflammation and pain in mice: role of TRPV1, oxidative stress, cytokines and NF-κB. Chem Biol Interact. 2015 Feb 25;228:88-99.

4-Hydroxychalcone

发表于由

天然产物 黄酮类 Flavonoids

4-Hydroxychalcone  纯度: 99.65%

4-Hydroxychalcone 是查尔酮代谢物，具有抗血管生成和消炎作用。 4-Hydroxychalcone 通过抑制生长因子途径抑制血管生成，无细胞毒性迹象。4-Hydroxychalcone 抑制 TNF-α 诱导的 NF-κB 途径活化并激活 BMP 信号传导，通过减轻小鼠的醛固酮过多症和肾脏损伤来降低抵抗性高血压 (RH)。

4-Hydroxychalcone

4-Hydroxychalcone Chemical Structure

CAS No. : 20426-12-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥550 In-stock
100 mg ￥500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

4-Hydroxychalcone 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • NF-κB Signaling Compound Library
  • Stem Cell Signaling Compound Library
  • Natural Product Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Differentiation Inducing Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Phenols Library
  • Pyroptosis Compound Library
  • Flavonoids Library
  • Anti-Breast Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Obesity Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library

生物活性

4-Hydroxychalcone is a chalcone metabolite with anti-angiogenic and anti-inflammatory activities. 4-Hydroxychalcone suppresses angiogenesis by suppression of growth factor pathway with no signs of cytotoxicity[1]. 4-Hydroxychalcone inhibits TNF-α induced NF-κB pathway activation and activates BMP signaling, reduces resistant hypertension (RH) by attenuating hyperaldosteronism and renal injury in mice[2].

IC50 & Target

NF-κB[2]
分子量

224.25

Formula

C15H12O2
CAS 号

20426-12-4
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
溶解性数据
In Vitro: 

DMSO : ≥ 250 mg/mL (1114.83 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.4593 mL 22.2965 mL 44.5931 mL
5 mM 0.8919 mL 4.4593 mL 8.9186 mL
10 mM 0.4459 mL 2.2297 mL 4.4593 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (9.28 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (9.28 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.08 mg/mL (9.28 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (9.28 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献

  • [1]. Varinska L, et al. Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone. Eur J Pharmacol. 2012 Sep 15;691(1-3):125-33.

    [2]. Qu Q, et al. 4-Hydroxychalcone attenuates hyperaldosteronism, inflammation, and renal injury in cryptochrome-null mice. Biomed Res Int. 2014;2014:603415.

Ginsenoside Rd(Synonyms: 人参皂苷 Rd; Gypenoside VIII)

发表于由

天然产物 糖类和糖苷 Saccharides and Glycosides

Ginsenoside Rd;(Synonyms: 人参皂苷 Rd; Gypenoside VIII) 纯度: 98.02%

Ginsenoside Rd 抑制 TNFα 诱导的 NF-κB 转录活性，IC50 为 12.05±0.82 μM。Ginsenoside Rd 抑制 COX-2 和 iNOS mRNA 的表达。Ginsenoside Rd 还抑制 Ca2+ 内流。Ginsenoside Rd 抑制CYP2D6，CYP1A2，CYP3A4 和 CYP2C9，IC50 分别为 58.0±4.5 μM，78.4±5.3 μM，81.7±2.6 μM 和 85.1±9.1 μM。

Ginsenoside Rd(Synonyms: 人参皂苷 Rd; Gypenoside VIII)

Ginsenoside Rd Chemical Structure

CAS No. : 52705-93-8

规格 价格 是否有货 数量
10;mM;*;1 mL in DMSO ￥1250 In-stock
5 mg ￥700 In-stock
10 mg ￥1200 In-stock
50 mg ; 询价 ;
100 mg ; 询价 ;

* Please select Quantity before adding items.

Ginsenoside Rd 相关产品

bull;相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Membrane Transporter/Ion Channel Compound Library
  • Metabolism/Protease Compound Library
  • Neuronal Signaling Compound Library
  • NF-kappa;B Signaling Compound Library
  • Stem Cell Signaling Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Human Endogenous Metabolite Compound Library
  • Anti-Aging Compound Library
  • Antioxidants Compound Library
  • Differentiation Inducing Compound Library
  • Glycoside Compound Library
  • Lipid Compound Library
  • Oxygen Sensing Compound Library
  • Anti-Cardiovascular Disease Compound Library
  • Medicine Food Homology Compound Library
  • Terpenoids Library
  • Pyroptosis Compound Library
  • Traditional Chinese Medicine Monomer Library
  • Neuroprotective Compound Library
  • Anti-Breast Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Anti-Obesity Compound Library
  • Transcription Factor Targeted Library
  • Food-Sourced Compound Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.

IC50 Target

NF-κB

12.05 mu;M (IC50, in HepG2 cells)

COX-2

;

L-type calcium channel

;

CYP2D6

58 mu;M (IC50)

CYP1A2

78.4 mu;M (IC50)

CYP3A4

81.7 mu;M (IC50)

CYP2C9

85.1 mu;M (IC50)

Human Endogenous Metabolite

;

体外研究
(In Vitro)

Ginsenoside Rd is one of the most abundant ingredients of Panax ginseng. Ginsenoside Rd significantly inhibits TNF-α-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 in HepG2 cells. Ginsenoside Rd also inhibits expression of COX-2 and iNOS mRNA and iNOS promoter activity in a dose-dependent manner. To determine nontoxic concentrations, HepG2 cells are treated with various concentrations (0.1, 1, and 10 μM) of compounds (e.g., Ginsenoside Rd) and cell viability is measured using an MTS assay. No compounds are significantly cytotoxic at up to 10 μM, indicating that NF-κB inhibition is not due to cell toxicity[1]. Ginsenoside Rd is one of the most abundant ingredients of Panax ginseng, protects the heart via multiple mechanisms including the inhibition of Ca2+ influx. Ginsenoside Rd reduces ICa,L peak amplitude in a concentration-dependent manner (IC50=32.4±7.1 μM)[2]. Ginsenoside Rd exhibits an inhibition against the activity of CYP2D6 in human liver microsomes with an IC50 of 58.0±4.5 μM, a weak inhibition against the activity of CYP1A2, CYP3A4, and CYP2C9 in human liver microsomes with IC50s of 78.4±5.3, 81.7±2.6, and 85.1±9.1, respectively, and an even weaker inhibition against the activity of CYP2A6 in human liver microsomes with an IC50 value of more than 100 μM[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Ginsenosides Rd is a major compound isolated from Gynostemma pentaphyllum that holistically improves gut microenvironment and induces anti-polyposis in ApcMin/+ mice. Six-weeks-old mice are subjected to Ginsenoside Rd treatment, before the appearance of the intestinal polyps. All the mice are monitored for food intake, water consumption, and weight changes. Throughout the experiment, no Rb3/ Ginsenoside Rd-associated weight loss in mice is observed. In addition, none of the treated mice show variations in food and water consumption. Whereas, the number and size of the polyps are effectively reduced by Ginsenoside Rd treatments[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

947.15

Formula

C48H82O18
CAS 号

52705-93-8
中文名称

人参皂苷 Rd
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20deg;C 3 years
4deg;C 2 years
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

DMSO : 100 mg/mL (105.58 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.0558 mL 5.2790 mL 10.5580 mL
5 mM 0.2112 mL 1.0558 mL 2.1116 mL
10 mM 0.1056 mL 0.5279 mL 1.0558 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂：;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.64 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂：;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.64 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂：;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.64 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献

  • [1]. Song SB, et al. Inhibition of TNF-α-mediated NF-κB Transcriptional Activity in HepG2 Cells by Dammarane-type Saponins from Panax ginseng Leaves. J Ginseng Res. 2012 Apr;36(2):146-52.

    [2]. Liu Y, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci. 2006 Jun;91(2):356-64.

    [3]. Lu C, et al. Inhibition of L-type Ca2+ current by ginsenoside Rd in rat ventricular myocytes. J Ginseng Res. 2015 Apr;39(2):169-77.

    [4]. Huang G, et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in ApcMin/+ mice. Sci Rep. 2017 Oct 2;7(1):12552.
Cell Assay
[1]

An MTS assay is used to analyze the effects of the compounds on cell viability. HepG2 cells are cultured overnight in a 96-well plate (1×104 cells/well). Cell viability is assessed after adding the compounds (e.g., Ginsenoside Rd; 0.1, 1, and 10 μM) for 24 h. The number of viable cells is determined by the A490nm of the dissolved formazan product, after addition of MTS for 30 min[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration
[3]

Mice[3]
Heterozygous male ApcMin/+ (C57BL/6J-ApcMin/+) mice are used. Total 32 male ApcMin/+ mice (aged 6 weeks) are divided into three groups; 10 mice in the control group and 22 mice equally divided for Rb3 and Rd treatments. The mice are daily gavage with a single dose of Ginsenoside Rb3 or Ginsenoside Rd at 20 mg/kg, or solvent control. The treatments are carried out for 8 consecutive weeks.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献

  • [1]. Song SB, et al. Inhibition of TNF-α-mediated NF-κB Transcriptional Activity in HepG2 Cells by Dammarane-type Saponins from Panax ginseng Leaves. J Ginseng Res. 2012 Apr;36(2):146-52.

    [2]. Liu Y, et al. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci. 2006 Jun;91(2):356-64.

    [3]. Lu C, et al. Inhibition of L-type Ca2+ current by ginsenoside Rd in rat ventricular myocytes. J Ginseng Res. 2015 Apr;39(2):169-77.

    [4]. Huang G, et al. Ginsenosides Rb3 and Rd reduce polyps formation while reinstate the dysbiotic gut microbiota and the intestinal microenvironment in ApcMin/+ mice. Sci Rep. 2017 Oct 2;7(1):12552.

Sanggenon C(Synonyms: 桑根酮 C)

发表于由

天然产物 黄酮类 Flavonoids

Sanggenon C (Synonyms: 桑根酮 C) 纯度: 97.30%

Sanggenon C 是一种黄烷酮 Diels-Alder 加合物化合物，从桑属 (Morus cathayana) 的根皮中分离出来的。 Sanggenon C 通过抑制钙调神经磷酸酶 /NFAT2 途径对心脏肥大和纤维化发挥保护作用。 Sanggenon C 通过抑制 NF-κB 活性，抑制 RAW264.7 细胞中诱导型一氧化氮合酶的表达，以及肿瘤坏死因子-α 刺激的细胞粘附和血管细胞粘附分子-1 的表达。 Sanggenon C 具有抗氧化和抗炎作用，也有抑制胰脂肪酶 (PL) 作用，IC50 为 3.00 μM。

Sanggenon C(Synonyms: 桑根酮 C)

Sanggenon C Chemical Structure

CAS No. : 80651-76-9

规格 价格 是否有货 数量
1 mg ￥1200 In-stock
5 mg ￥3000 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Sanggenon C 相关产品

•相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus

生物活性

Sanggenon C is a flavanone Diels-Alder adduct compound, which is isolated from the root bark of Morus cathayana. Sanggenon C exerts protective effects against cardiac hypertrophy and fibrosis via suppression of the calcineurin/NFAT2 pathway. Sanggenon C inhibits inducible nitric oxide synthase expression in RAW264.7 cells, and tumor necrosis factor-α-stimulated cell adhesion and vascular cell adhesion molecule-1 expression, by suppressing NF-κB activity[1]. Sanggenon C possesses antioxidant, anti-inflammatory activities and inhibits Pancreatic lipase (PL) with the an IC50 of 3.00 μM[2].

IC50 & Target[1]

NF-κB

 

分子量

708.71

Formula

C40H36O12
CAS 号

80651-76-9
中文名称

桑根酮 C
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

-20°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (141.10 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.4110 mL 7.0551 mL 14.1101 mL
5 mM 0.2822 mL 1.4110 mL 2.8220 mL
10 mM 0.1411 mL 0.7055 mL 1.4110 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (3.53 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.53 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。
参考文献

  • [1]. Xiao L, et al. Sanggenon C protects against pressure overload induced cardiac hypertrophy via the calcineurin/NFAT2 pathway. Mol Med Rep. 2017 Oct;16(4):5338-5346.

    [2]. Hou XD , et al. Natural constituents from Cortex Mori Radicis as new pancreatic lipase inhibitors. Bioorg Chem. 2018 Oct;80:577-584.